

Hepatocellular Cancer

Metastatic Disease (somatic)

When and what should be tested?

- Consider in atypical cases/clinical trials and mixed histology. There is no established indication for routine molecular testing for all cases of HCC.
- Treatment eligible
- Metastatic disease
- At time of initial diagnosis or recurrence
- Tissue or liquid

FDA/NCCN approved

- dMMR/MSI-H
- TMB
- NTRK
- RET
- BRAF V600E
- HER2

Emerging

- IDH1
- IDH2
- FGF
- KRAS
- Expanded NGS panel

Informational Considerations